Scalper1 News
Shares of generic drug maker Perrigo (PRGO) rose as much as 3.1% Tuesday after BMO Capital Markets launched coverage with an outperform rating, saying Perrigo stock is undervalued regardless of whether Mylan (MYL) succeeds in acquiring the company. Analyst David Maris wrote that trends favor Perrigo’s business model, which is divided between private-label over-the-counter and prescription generic drugs. “The continued movement of consumers from Scalper1 News
Scalper1 News